Bugrim A, Nikolskaya T, Nikolsky Y: Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discovery Today. 2004, 9: 127-135. 10.1016/S1359-6446(03)02971-4
Article
CAS
PubMed
Google Scholar
van de Waterbeemd H, Gifford E: ADMET in silico modelling: Towards prediction paradise?. Nature Reviews Drug Discovery. 2003, 2: 192-204. 10.1038/nrd1032
Article
CAS
PubMed
Google Scholar
Kramer JA, Sagartz JE, Morris DL: The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov. 2007, 6: 636-649. 10.1038/nrd2378
Article
CAS
PubMed
Google Scholar
Huisinga W, Telgmann R, Wulkow M: The virtual laboratory approach to pharmacokinetics: design principles and concepts. Drug Discovery Today. 2006, 11: 800-805. 10.1016/j.drudis.2006.07.001
Article
CAS
PubMed
Google Scholar
Kitano H: Systems biology: a brief overview. Science. 2002, 295: 1662-1664. 10.1126/science.1069492
Article
CAS
PubMed
Google Scholar
Spivey A: Systems biology - The big picture. Environmental Health Perspectives. 2004, 112: A938-A943.
Article
PubMed Central
PubMed
Google Scholar
Andersson TB, Bredberg E, Ericsson H, Sjoberg H: An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metabolism and Disposition. 2004, 32: 715-721. 10.1124/dmd.32.7.715
Article
CAS
PubMed
Google Scholar
Clarke SE, Jeffrey P: Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica. 2001, 31: 591-598. 10.1080/00498250110057350
Article
CAS
PubMed
Google Scholar
Lin JH: Sense and nonsense in the prediction of drug-drug interactions. Current Drug Metabolism. 2000, 1: 305-331. 10.2174/1389200003338947
Article
CAS
PubMed
Google Scholar
de Groot MJ, Ekins S: Pharmacophore modeling of cytochromes P450. Advanced Drug Delivery Reviews. 2002, 54: 367-383. 10.1016/S0169-409X(02)00009-1
Article
CAS
PubMed
Google Scholar
Gasteiger J, Reitz M, Han YQ, Sacher O: Analyzing biochemical pathways using neural networks and genetic algorithms. Australian Journal of Chemistry. 2006, 59: 854-858. 10.1071/CH06140.
Article
CAS
Google Scholar
Korolev D, Balakin KV, Nikolsky Y, Kirillov E, Ivanenkov YA, Savchuk NP, Ivashchenko AA, Nikolskaya T: Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. Journal of Medicinal Chemistry. 2003, 46: 3631-3643. 10.1021/jm030102a
Article
CAS
PubMed
Google Scholar
Lewis DFV, Ioannides C, Parke DV: An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation. Drug Metabolism Reviews. 1998, 30: 709-737. 10.3109/03602539808996328
Article
CAS
PubMed
Google Scholar
Lewis DFV, Ioannides C, Parke DV: Further evaluation of COMPACT, the molecular orbital approach for the prospective safety evaluation of chemicals. Mutation Research-Genetic Toxicology and Environmental Mutagenesis. 1998, 412: 41-54. 10.1016/S1383-5718(97)00145-9
Article
CAS
PubMed
Google Scholar
Terfloth L, Bienfait B, Gasteiger J: Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates. Journal of Chemical Information and Modeling. 2007, 47: 1688-1701. 10.1021/ci700010t
Article
CAS
PubMed
Google Scholar
Zhang EY, Phelps MA, Cheng C, Ekins S, Swaan PW: Modeling of active transport systems. Advanced Drug Delivery Reviews. 2002, 54: 329-354. 10.1016/S0169-409X(02)00007-8
Article
CAS
PubMed
Google Scholar
Ekins S, Erickson JA: A pharmacophore for human pregnane X receptor ligands. Drug Metabolism and Disposition. 2002, 30: 96-99. 10.1124/dmd.30.1.96
Article
CAS
PubMed
Google Scholar
Ekins S, Mirny L, Schuetz EG: A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXR alpha, and LXR beta. Pharmaceutical Research. 2002, 19: 1788-1800. 10.1023/A:1021429105173
Article
CAS
PubMed
Google Scholar
Hou TJ, Wang JM, Li YY: ADME evaluation in drug discovery. 8. The prediction of human intestinal absorption by a support vector machine. Journal of Chemical Information and Modeling. 2007, 47: 2408-2415. 10.1021/ci7002076
Article
CAS
PubMed
Google Scholar
Hou TJ, Wang JM, Zhang W, Xu XJ: ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?. Journal of Chemical Information and Modeling. 2007, 47: 460-463. 10.1021/ci6003515
Article
CAS
PubMed
Google Scholar
Hou TJ, Zhang W, Xia K, Qiao XB, Xu XJ: ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. Journal of Chemical Information and Computer Sciences. 2004, 44: 1585-1600.
CAS
PubMed
Google Scholar
Leonard JT, Roy K: On selection of training and test sets for the development of predictive QSAR models. Qsar & Combinatorial Science. 2006, 25: 235-251. 10.1002/qsar.200510161
Article
CAS
Google Scholar
Rostami-Hodjegan A, Tucker GT: Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews Drug Discovery. 2007, 6: 140-148. 10.1038/nrd2173
Article
CAS
PubMed
Google Scholar
Andersen ME: Development of Physiologically-Based Pharmacokinetic and Physiologically-Based Pharmacodynamic Models for Applications in Toxicology and Risk Assessment. Toxicology Letters. 1995, 79: 35-44. 10.1016/0378-4274(95)03355-O
Article
CAS
PubMed
Google Scholar
Gerlowski LE, Jain RK: Physiologically Based Pharmacokinetic Modeling - Principles and Applications. Journal of Pharmaceutical Sciences. 1983, 72: 1103-1127. 10.1002/jps.2600721003
Article
CAS
PubMed
Google Scholar
Reddy M, Yang RS, Andersen ME, Clewell I, H J: Phyiologically Based Pharmacokinetic Modelling. 2005, John Wiley & Sons,
Book
Google Scholar
Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Lipscomb JC, Schlosser P, Chiu WA, Krishnan K: Approaches for applications of physiologically based pharmacokinetic models in risk assessment. Journal of Toxicology and Environmental Health-Part B-Critical Reviews. 2008, 11: 519-547. 10.1080/10937400701724337.
Article
CAS
Google Scholar
Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W: PK-Sim®: a physiologically based pharmacokinetic 'whole-body' model. Biosilico. 2003, 1:
Google Scholar
Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW: Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Current Topics in Medicinal Chemistry. 2005, 5: 1033-1038. 10.2174/156802605774297038
Article
CAS
PubMed
Google Scholar
Hop CECA, Cole MJ, Davidson RE, Duignan DB, Federico J, Janiszewski JS, Jenkins K, Krueger S, Lebowitz R, Liston TE, Mitchell W, Snyder M, Steyn SJ, Soglia JR, Taylor C, Troutman MD, Umland J, West M, Whalen KM, Zelesky V, Zhao SX: High Throughput ADME Screening: Practical Considerations, Impact on the Portfolio and Enabler of In Silico ADME Models. Current Drug Metabolism. 2008, 9: 847-853. 10.2174/138920008786485092
Article
CAS
PubMed
Google Scholar
Singh SS: Preclinical pharmacokinetics: An approach towards safer and efficacious drugs. Current Drug Metabolism. 2006, 7: 165-182. 10.2174/138920006775541552
Article
CAS
PubMed
Google Scholar
Nestorov I: Whole-body physiologically based pharmacokinetic models. Expert Opinion on Drug Metabolism & Toxicology. 2007, 3: 235-249. 10.1517/17425255.3.2.235
Article
CAS
Google Scholar
Baker M, Parton T: Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica. 2007, 37: 1110-1134. 10.1080/00498250701658296
Article
CAS
PubMed
Google Scholar
Poirier A, Lave T, Portmann R, Brun ME, Senner F, Kansy M, Grimm HP, Funk C: Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model. Drug Metabolism and Disposition. 2008, 36: 2434-2444. 10.1124/dmd.108.020750
Article
CAS
PubMed
Google Scholar
Paine SW, Parker AJ, Gardiner P, Webborn PJH, Riley RJ: Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metabolism and Disposition. 2008, 36: 1365-1374. 10.1124/dmd.107.019455
Article
CAS
PubMed
Google Scholar
Thasler WE, Weiss TS, Schillhorn K, Stoll PT, Irrgang B, Jauch KW: Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank. 2003, 4: 49-56. 10.1023/A:1026392429112
Article
PubMed
Google Scholar
Nussler AK, Nussler NC, Merk V, Brulport M, Schormann W, Yao P, Hengstler JG: The Holy grail of hepatocyte culturing and therapeutic use. Strategies in Regenerative Medicine. Edited by: Santin M. 2008, New York: Springer,
Google Scholar
Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM: UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther. 2009, 87: 65-73.
Article
PubMed
Google Scholar
Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM: Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003, 38: 978-988.
Article
CAS
PubMed
Google Scholar
Langenfeld E, Zanger UM, Jung K, Meyer HE, Marcus K: Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics. 2009, 9: 2313-2323. 10.1002/pmic.200800680
Article
CAS
PubMed
Google Scholar
Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, Loi CM: Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007, 35: 1315-1324. 10.1124/dmd.107.015230
Article
CAS
PubMed
Google Scholar
Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002, 30: 505-512. 10.1124/dmd.30.5.505
Article
CAS
PubMed
Google Scholar
Kearney AS, Crawford LF, Mehta SC, Radebaugh GW: The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res. 1993, 10: 1461-1465. 10.1023/A:1018923325359
Article
CAS
PubMed
Google Scholar
Aviram M, Rosenblat M: Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol. 2008, 477: 259-276. 10.1007/978-1-60327-517-0_20
Article
CAS
PubMed
Google Scholar
Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN: Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem. 2000, 275: 33435-33442. 10.1074/jbc.M004543200
Article
CAS
PubMed
Google Scholar
Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN: Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005, 46: 1239-1247. 10.1194/jlr.M400511-JLR200
Article
CAS
PubMed
Google Scholar
Gouedard C, Koum-Besson N, Barouki R, Morel Y: Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol. 2003, 63: 945-956. 10.1124/mol.63.4.945
Article
CAS
PubMed
Google Scholar
Khersonsky O, Tawfik DS: Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry. 2005, 44: 6371-6382. 10.1021/bi047440d
Article
CAS
PubMed
Google Scholar
Christians U, Jacobsen W, Floren LC: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. Pharmacol Ther. 1998, 80: 1-34. 10.1016/S0163-7258(98)00016-3
Article
CAS
PubMed
Google Scholar
Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U: Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000, 28: 1369-1378.
CAS
PubMed
Google Scholar
Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T: Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica. 2004, 34: 961-971. 10.1080/00498250400015319
Article
CAS
PubMed
Google Scholar
Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG: Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica. 2008, 38: 1240-1251. 10.1080/00498250802334391
Article
CAS
PubMed
Google Scholar
Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, Siegmund W, Warzok R, Kroemer HK: Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clinical Pharmacology & Therapeutics. 2006, 80: 607-620. 10.1016/j.clpt.2006.09.010
Article
CAS
Google Scholar
Lau YY, Huang Y, Frassetto L, Benet LZ: effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007, 81: 194-204. 10.1038/sj.clpt.6100038
Article
CAS
PubMed
Google Scholar
Nishimura M, Naito S: Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005, 20: 452-477. 10.2133/dmpk.20.452
Article
CAS
PubMed
Google Scholar
Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, Kim RB, Tirona RG: Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010, 106: 297-306. 10.1161/CIRCRESAHA.109.203596
Article
CAS
PubMed
Google Scholar
Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metabolism and Disposition. 2007, 35: 1333-1340. 10.1124/dmd.107.014902
Article
CAS
PubMed
Google Scholar
Li L, Lee TK, Meier PJ, Ballatori N: Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem. 1998, 273: 16184-16191. 10.1074/jbc.273.26.16184
Article
CAS
PubMed
Google Scholar
Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N: Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol. 2007, 293: G271-278. 10.1152/ajpgi.00075.2007
Article
CAS
PubMed
Google Scholar
Kilford PJ, Gertz M, Houston JB, Galetin A: Hepatocellular binding of drugs: Correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metabolism and Disposition. 2008, 36: 1194-1197. 10.1124/dmd.108.020834
Article
CAS
PubMed
Google Scholar
Bogman K, Peyer AK, Torok M, Kusters E, Drewe J: HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol. 2001, 132: 1183-1192. 10.1038/sj.bjp.0703920
Article
PubMed Central
CAS
PubMed
Google Scholar
Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000, 40: 91-98. 10.1177/00912700022008612
Article
CAS
PubMed
Google Scholar
Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005, 33: 537-546. 10.1124/dmd.104.002477
Article
CAS
PubMed
Google Scholar
Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T: Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004, 21: 1686-1691.
Article
CAS
PubMed
Google Scholar
Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K: Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharmaceutical Research. 2006, 23: 506-512. 10.1007/s11095-005-9371-5
Article
CAS
PubMed
Google Scholar
Chandra P, Brouwer KLR: The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharmaceutical Research. 2004, 21: 719-735.
Article
CAS
PubMed
Google Scholar
Hamelin BA, Turgeon J: Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends in Pharmacological Sciences. 1998, 19: 26-37. 10.1016/S0165-6147(97)01147-4
Article
CAS
PubMed
Google Scholar
Austin RP, Barton P, Mohmed S, Riley RJ: The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos. 2005, 33: 419-425.
Article
CAS
PubMed
Google Scholar
Hallifax D, Houston JB: Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos. 2006, 34: 1829-1836. 10.1124/dmd.106.010413
Article
CAS
PubMed
Google Scholar
Schwartlander R, Schmid J, Brandenburg B, Katenz E, Wolfgang F, Vondran R, Pless G, Cheng XD, Pascher A, Neuhaus P, Sauer IM: Continuously microscopically observed and process-controlled cell culture within the SlideReactor: Proof of a new concept for cell characterization. Tissue Engineering. 2007, 13: 187-196. 10.1089/ten.2006.0071
Article
CAS
PubMed
Google Scholar
Toutain PL, Bousquet-Melou A: Free drug fraction vs free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther. 2002, 25: 460-463. 10.1046/j.1365-2885.2002.00442.x
Article
CAS
PubMed
Google Scholar
Bartholome K, Rius M, Letschert K, Keller D, Timmer J, Keppler D: Data-based mathematical modeling of vectorial transport across double-transfected polarized cells. Drug Metab Dispos. 2007, 35: 1476-1481. 10.1124/dmd.107.015636
Article
CAS
PubMed
Google Scholar
Poland J, Zell A: Main Vector Adaptation: A CMA Variant with Linear Time and Space Complexity. Proceedings of the Genetic and Evolutionary Computation Conference (GECCO-2001); Washington, D.C., USA. 2001, 312-317.
Google Scholar
Deuflhard P, Hairer E, Zugck J: One-Step and Extrapolation Methods for Differential-Algebraic Systems. Numerische Mathematik. 1987, 51: 501-516. 10.1007/BF01400352.
Article
Google Scholar
Prueksaritanont T, Ma B, Fang X, Subramanian R, Yu J, Lin JH: beta-Oxidation of simvastatin in mouse liver preparations. Drug Metab Dispos. 2001, 29: 1251-1255.
CAS
PubMed
Google Scholar
Deng WJ, Nie S, Dai J, Wu JR, Zeng R: Proteome, phosphoproteome, and hydroxyproteome of liver mitochondria in diabetic rats at early pathogenic stages. Mol Cell Proteomics. 2010, 9: 100-116. 10.1074/mcp.M900020-MCP200
Article
PubMed Central
CAS
PubMed
Google Scholar
Motawi TM, Hashem RM, Rashed LA, El-Razek SM: Comparative study between the effect of the peroxisome proliferator activated receptor-alpha ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5'-AMP-activated protein kinase-alpha1 in high-fat fed rats. J Pharm Pharmacol. 2009, 61: 1339-1346.
Article
CAS
PubMed
Google Scholar
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3
Article
CAS
PubMed
Google Scholar
Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, Lameire NH: Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant. 2003, 18: 967-976. 10.1093/ndt/gfg048
Article
CAS
PubMed
Google Scholar
Launay-Vacher V, Izzedine H, Deray G: Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol. 2005, 101: 9-17. 10.1016/j.ijcard.2004.04.005
Article
PubMed
Google Scholar
Kantola T, Kivisto KT, Neuvonen PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998, 64: 58-65. 10.1016/S0009-9236(98)90023-6
Article
CAS
PubMed
Google Scholar
Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001, 276: 35669-35675. 10.1074/jbc.M103792200
Article
CAS
PubMed
Google Scholar
Cui YH, Konig J, Keppler D: Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Molecular Pharmacology. 2001, 60: 934-943.
CAS
PubMed
Google Scholar